177 related articles for article (PubMed ID: 14676110)
1. Phase II study of imatinib in patients with small cell lung cancer.
Johnson BE; Fischer T; Fischer B; Dunlop D; Rischin D; Silberman S; Kowalski MO; Sayles D; Dimitrijevic S; Fletcher C; Hornick J; Salgia R; Le Chevalier T
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5880-7. PubMed ID: 14676110
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
Chao J; Budd GT; Chu P; Frankel P; Garcia D; Junqueira M; Loera S; Somlo G; Sato J; Chow WA
Anticancer Res; 2010 Feb; 30(2):547-52. PubMed ID: 20332468
[TBL] [Abstract][Full Text] [Related]
6. Is KIT an important therapeutic target in small cell lung cancer?
Heinrich MC
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5825-8. PubMed ID: 14676102
[No Abstract] [Full Text] [Related]
7. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.
Einhorn LH; Brames MJ; Heinrich MC; Corless CL; Madani A
Am J Clin Oncol; 2006 Feb; 29(1):12-3. PubMed ID: 16462496
[TBL] [Abstract][Full Text] [Related]
8. Kit expression in small cell carcinomas of the lung: effects of chemotherapy.
Rossi G; Cavazza A; Marchioni A; Migaldi M; Bavieri M; Facciolongo N; Petruzzelli S; Longo L; Tamberi S; Crinò L
Mod Pathol; 2003 Oct; 16(10):1041-7. PubMed ID: 14559988
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial.
Altundag O; Altundag K; Boruban C; Silay YS; Turen S
Cancer; 2005 Nov; 104(9):2033-4; author reply 2034. PubMed ID: 16161057
[No Abstract] [Full Text] [Related]
10. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.
Dy GK; Miller AA; Mandrekar SJ; Aubry MC; Langdon RM; Morton RF; Schild SE; Jett JR; Adjei AA
Ann Oncol; 2005 Nov; 16(11):1811-6. PubMed ID: 16087693
[TBL] [Abstract][Full Text] [Related]
13. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Heinrich MC; Joensuu H; Demetri GD; Corless CL; Apperley J; Fletcher JA; Soulieres D; Dirnhofer S; Harlow A; Town A; McKinley A; Supple SG; Seymour J; Di Scala L; van Oosterom A; Herrmann R; Nikolova Z; McArthur AG;
Clin Cancer Res; 2008 May; 14(9):2717-25. PubMed ID: 18451237
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Bond M; Bernstein ML; Pappo A; Schultz KR; Krailo M; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2008 Feb; 50(2):254-8. PubMed ID: 17262795
[TBL] [Abstract][Full Text] [Related]
15. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.
Micke P; Basrai M; Faldum A; Bittinger F; Rönnstrand L; Blaukat A; Beeh KM; Oesch F; Fischer B; Buhl R; Hengstler JG
Clin Cancer Res; 2003 Jan; 9(1):188-94. PubMed ID: 12538468
[TBL] [Abstract][Full Text] [Related]
16. Imatinib in small cell lung cancer.
Soria JC; Johnson BE; Chevalier TL
Lung Cancer; 2003 Aug; 41 Suppl 1():S49-53. PubMed ID: 12867062
[TBL] [Abstract][Full Text] [Related]
17. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
Baruchel S; Sharp JR; Bartels U; Hukin J; Odame I; Portwine C; Strother D; Fryer C; Halton J; Egorin MJ; Reis RM; Martinho O; Stempak D; Hawkins C; Gammon J; Bouffet E
Eur J Cancer; 2009 Sep; 45(13):2352-9. PubMed ID: 19505817
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
[TBL] [Abstract][Full Text] [Related]
19. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of KIT expression in small cell lung cancer.
López-Martin A; Ballestín C; Garcia-Carbonero R; Castaño A; Lopez-Ríos F; López-Encuentra A; Sánchez-Cespedes M; Castellano D; Bartolomé A; Cortés-Funes H; Paz-Ares L
Lung Cancer; 2007 Jun; 56(3):405-13. PubMed ID: 17420067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
